Frontlight ResearchEarly access
Not yet taking people in FrancePhase 1
Tests OT-C001 cell therapy in adults with relapsed or hard-to-treat large B-cell lymphoma
Tests OT-C001, a treatment made from natural killer immune cells, in adults with lymphoma.
Key facts
- Who runs it
- Emercell SAS
- Where
- Montpellier Cedex 05 and Toulouse Cedex 9, FranceSee the 2 sites
- Trial code
- Registry title
- A first-in-human, open-label, clinical study to assess the safety, tolerability, and activity of OT-C001 (amplified/activated allogenic natural killer cells) in patients with relapsed/refractory diffuse large B-cell lymphoma
- Status
- Not yet recruiting
- Phase
- Phase 1
- People taking part
- 10 people, planned
- Started
- 1 Jun 2025
- Expected to end
- 31 Dec 2027
- Type of study
- Interventional
- Record updated
- 6 November 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults whose diffuse large B-cell lymphoma has come back or has not responded to treatment. It tests the safety and activity of OT-C001, a natural killer cell therapy.
- Age
- 18 years or older
- Sex
- All sexes can join
- Disease stage
- Diffuse large B-cell lymphoma that has relapsed (come back) or is refractory (did not respond to treatment)
Main reasons for not taking part
- Healthy volunteers cannot join
Where in France
- CHU de MontpellierMontpellier Cedex 05, FranceNot yet recruiting
- Oncopole Claudius RegaudToulouse Cedex 9, FranceNot yet recruiting
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record
Print a page for my doctorData and sources
- Registry record
- Listed on the EU's official list of trials (CTIS).How to verify a trial in the registry
- Plain-language title
- Tests OT-C001 cell therapy in adults with relapsed or hard-to-treat large B-cell lymphomaGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 9 November 2026.
- Record updated
- 6 November 2026